205 related articles for article (PubMed ID: 37799492)
1. Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients.
Gagg H; Williams ST; Conroy S; Myers KN; McGarrity-Cottrell C; Jones C; Helleday T; Rantala J; Rominiyi O; Danson SJ; Collis SJ; Wells G
F1000Res; 2023; 12():954. PubMed ID: 37799492
[TBL] [Abstract][Full Text] [Related]
2. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
3. Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma.
Taylor JT; Ellison S; Pandele A; Wood S; Nathan E; Forte G; Parker H; Zindy E; Elvin M; Dickson A; Williams KJ; Karabatsou K; McCabe M; McBain C; Bigger BW
Neuro Oncol; 2020 Sep; 22(9):1289-1301. PubMed ID: 32227096
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I; Kleijn A; Ju J; Jimenez-Cowell K; Fabro F; Klein M; Chi Yen RT; Balvers RK; Li Y; Stubbs AP; Kers TV; Kros JM; Lawler SE; Beerepoot LV; Kremer A; Idbaih A; Verreault M; Byrne AT; O'Farrell AC; Connor K; Biswas A; Salvucci M; Prehn JHM; Lambrechts D; Dilcan G; Lodi F; Arijs I; van den Bent MJ; Dirven CMF; Leenstra S; ; Lamfers MLM
Br J Cancer; 2023 Oct; 129(8):1327-1338. PubMed ID: 37620410
[TBL] [Abstract][Full Text] [Related]
6. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
[TBL] [Abstract][Full Text] [Related]
7. Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Marques-Torrejon MA; Gangoso E; Pollard SM
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29196443
[TBL] [Abstract][Full Text] [Related]
8. Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity.
Jones CG; Vanderlinden A; Rominiyi O; Collis SJ
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473223
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
10. Precision oncology using ex vivo technology: a step towards individualised cancer care?
Williams ST; Wells G; Conroy S; Gagg H; Allen R; Rominiyi O; Helleday T; Hullock K; Pennington CEW; Rantala J; Collis SJ; Danson SJ
Expert Rev Mol Med; 2022 Oct; 24():e39. PubMed ID: 36184897
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
12. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
15. The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma.
Aderetti DA; Hira VVV; Molenaar RJ; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):346-354. PubMed ID: 29684521
[TBL] [Abstract][Full Text] [Related]
16. A three-dimensional (3D) organotypic microfluidic model for glioma stem cells - Vascular interactions.
Truong D; Fiorelli R; Barrientos ES; Melendez EL; Sanai N; Mehta S; Nikkhah M
Biomaterials; 2019 Apr; 198():63-77. PubMed ID: 30098794
[TBL] [Abstract][Full Text] [Related]
17. Dual-drug loaded nanomedicine hydrogel as a therapeutic platform to target both residual glioblastoma and glioma stem cells.
Bozzato E; Tsakiris N; Paquot A; Muccioli GG; Bastiancich C; Préat V
Int J Pharm; 2022 Nov; 628():122341. PubMed ID: 36341916
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
19. The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Charbonneau M; Harper K; Brochu-Gaudreau K; Perreault A; Roy LO; Lucien F; Tian S; Fortin D; Dubois CM
Neuro Oncol; 2023 Sep; 25(9):1605-1616. PubMed ID: 36821432
[TBL] [Abstract][Full Text] [Related]
20. Novel nor-monoterpenoid indole alkaloids inhibiting glioma stem cells from fruits of Alstonia scholaris.
Wang B; Dai Z; Yang XW; Liu YP; Khan A; Yang ZF; Huang WY; Wang XH; Zhao XD; Luo XD
Phytomedicine; 2018 Sep; 48():170-178. PubMed ID: 30195875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
